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ABSTRACT 
BACKGROUND:  A large proportion of colorectal cancers (CRC) are thought to be associated with 
unhealthy dietary and lifestyle exposures, particularly energy excess, obesity, hyperinsulinemia and 
hyperglycemia. It has been suggested that these processes stimulate the production of toxic reactive 
carbonyls from sugars such as glyceraldehyde. Glyceraldehyde contributes to the production of a 
group of compounds known as glyceraldehyde-derived advanced glycation end-products (glycer-
AGEs) which may promote CRC through their pro-inflammatory and pro-oxidative properties. The 
objective of this study nested within a prospective cohort was to explore the association of 
circulating glycer-AGEs with risk of CRC.  
METHODS:  1,055 CRC cases (colon n = 659; rectal n = 396) were matchced (1:1) to control subjects. 
Circulating glycer-AGEs were measured by a competitive enzyme-linked immunosorbent assay. 
Multivariable conditional logistic regression models were used to calculate odds ratios (OR) and 95% 
confidence intervals (95% CI), adjusting for potential confounding factors including smoking, alcohol, 
physical activity, body mass index, and diabetes status.  
RESULTS:  Elevated glycer-AGEs levels were not associated with CRC risk (highest vs. lowest quartile, 
1.10; 95% CI, 0.82-1.49). Sub-group analyses showed possible divergence by anatomical sub-sites (OR 
for colon cancer = 0.83; 95% CI, 0.57-1.22; OR for rectal cancer = 1.90; 95% CI, 1.14-3.19; pheterogeneity = 
0.14).  
CONCLUSIONS:  In this prospective study, circulating glycer-AGEs were not associated with risk of 
colon cancer, but showed a positive association with the risk of rectal cancer.  
IMPACT:  Further research is needed to clarify the role of toxic products of carbohydrate metabolism 
and energy excess in CRC development. 
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INTRODUCTION 
 Colorectal cancer (CRC) is the third most common cancer in men and the second in women 
worldwide (1). The incidence of CRC varies approximately 25-fold in different world regions with high 
risk in developed countries (2). Moreover, it has been observed that the number of new CRC cases is 
increasing in countries adopting Western dietary and lifestyle patterns, observations which strongly 
suggest a role for environmental factors in its development (3). Many environmental factors, such as 
Western-type diet, physical inactivity, and abdominal obesity have been implicated in CRC aetiology 
(4). Some of the key metabolic consequences of these exposures are hyperinsulinemia, 
hyperglycemia, inflammation, and oxidative stress, all of which have been proposed as major 
underlying mechanisms for CRC development (5, 6). Interestingly, it has been proposed that 
interaction between processes of metabolic over-nutrition with inflammation and oxidative stress 
can lead to the production of reactive carbonyls, a group of highly toxic and possibly carcinogenic 
compounds, which in turn also have pro-inflammatory and pro-oxidative properties of their own (7). 
One example of this reaction, which has been well-observed in vitro, is the conversion of 
glyceraldehyde, an early product of glycolysis, to reactive carbonyls by reactive oxygen species (ROS) 
(8). Glyceraldehyde contributes to the production of a group of compounds known as 
glyceraldehyde-derived advanced glycation end-products (glycer-AGEs) (9). They belong to the larger 
family of advanced glycation end-products (AGEs), which are stable end-products of the non-
enzymatic glycation reaction between reactive carbonyls and free amino groups of proteins, lipids, or 
nucleic acids (10, 11). They can be formed either exogenously in cooking and cigarette smoking 
processes or endogenously in tissues in the presence of ROS resulting from inflammation or other 
processes (12, 13). Glycer-AGEs are the main component of what is considered the most toxic sub-
group of AGEs, also referred to as toxic-AGEs (14). It has been observed that glycer-AGEs can form in 
vivo from both reactive carbonyls and as a direct consequence of sugar metabolism (15, 16). Thus, it 
is plausible that the circulating concentration of glycer-AGEs, aside from having direct inflammatory 
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and oxidative properties, may also be an indicator of the extent of direct exposures to reactive 
carbonyl species.  
 AGEs in general have been implicated in the development of diabetes (17, 18) and in ocular 
(19), renal (20), cardiovascular (21), and some neurodegenerative disorders (22), as well as in several 
cancers (23, 24). For their part, glycer-AGEs have been shown to be cytotoxic in vitro (25, 26) and 
findings from animal studies suggest involvement in the pathogenesis of insulin resistance and 
diabetes (27) as well as its complications (28). Human studies suggest the involvement of glycer-AGEs 
in the development of Alzheimer’s disease (29), non-alcoholic steatohepatitis (30), vascular 
inflammation (31) and some rare disorders (32, 33). In addition to their potential direct effects, some 
evidence indicates that glycer-AGEs interact strongly with the receptor for AGEs (RAGE) to cause 
inflammatory and oxidative responses (28, 34)– which are suspected in the development of various 
cancers, including CRC (35-37). In view of their apparent direct cytotoxicity, adverse effects on cell 
function and involvement in inflammatory and oxidative processes, a role for glycer-AGEs in CRC 
development is plausible, but has yet to be examined in studies on humans. In this study, nested 
within the large multi-national European Prospective Investigation into Cancer and Nutrition (EPIC) 
cohort, we investigated the association of circulating concentrations of glycer-AGEs with risk of CRC. 
We hypothesize that higher concentrations of glycer-AGEs would be positively associated with risk of 
CRC development.   
 
MATERIALS AND METHODS 
Study population and data collection  
We used a case-control design nested within the EPIC cohort, a large prospective cohort 
study with over 520,000 subjects enrolled from 23 centres in 10 Western European countries 
(Denmark, France, Greece, Germany, Italy, Netherlands, Norway, Spain, Sweden, and United 
Kingdom).  The rationale and methods of EPIC, including information on dietary assessment methods, 
blood collection protocols, and follow-up procedures, have been previously reviewed (38).  Briefly, 
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individuals who were eligible for the study were selected from the general population of a specific 
geographical area, town, or province.  Exceptions included the French sub-cohort, which is based on 
members of the health insurance system or state-school employees, the Utrecht (Netherlands) sub-
cohort, which is based on women who underwent screening for breast cancer, and the Oxford (UK) 
sub-cohort, which targeted recruitment towards health-conscious people, including vegetarians. 
Between 1992 and 1998, standardized lifestyle and personal history questionnaires, anthropometric 
data, and blood samples were collected from most participants at recruitment. Diet over the 
previous 12 months was assessed at recruitment by validated country-specific questionnaires 
designed to ensure high compliance and improved measures of local dietary habits (39). In each of 
the study centres, either fasting or non-fasting blood samples of at least 30 mL were drawn from 
those participants who provided a blood sample and stored at 5°C  to 10°C, protected from light, and 
transported to local laboratories for processing and aliquoting as previously described (38, 39). In all 
countries, except Denmark and Sweden, blood was separated in the local EPIC centres and stored at 
the International Agency for Research on Cancer (Lyon, France; -196°C, nitrogen vapour).  In 
Denmark, blood samples were stored locally at -150°C under nitrogen vapour.  In Sweden, samples 
were stored in -80°C freezers.   
Follow-up for cancer incidence and vital status  
Vital status follow-up (98.4% complete) is collected by record linkage with regional and/or 
national mortality registries in all countries except Germany and Greece, and the Italian centre of 
Naples, where data are collected actively. Cancer incidence is determined through record linkage 
with regional cancer registries (Denmark, other Italian centres, the Netherlands, Norway, Spain, 
Sweden, and United Kingdom; for this analysis complete up to June 2003) or via a combination of 
methods, including linkage with health insurance records, contacts with cancer and pathology 
registries, and active follow-up through study subjects or their next-of-kin (France, Germany, and 
Greece; for this analysis complete up to June 2002).   
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Nested case-control study design and selection of study subjects 
Case ascertainment and selection 
Colon cancers were defined as incident tumours in the cecum, appendix, ascending colon, 
hepatic flexure, transverse colon, splenic flexure, and descending and sigmoid (C18.0 – C18.7, 
according to the 10th Revision of the International Statistical Classification of Diseases, Injury, and 
Cause of Death), as well as tumours that were overlapping or unspecified (C18.8 and C18.9). Rectal 
cancers were defined as incident tumours occurring at the recto-sigmoid junction (C19) or rectum 
(C20). Subjects with anal canal tumours were excluded from the study. CRC is defined as a 
combination of the colon and rectal cancer cases.  
After exclusions (225 cases for insufficient remaining bio-sample, 26 cases for missing 
laboratory values of glycer-AGEs and 29 cases with incomplete matching), a total of 1,055 first 
incident CRC cases (colon n = 659; rectal n = 396) were identified.  
Control selection 
For selection of control subjects, an incidence density sampling protocol was applied. For 
each case one control subject was chosen at random among appropriate risk sets consisting of all 
cohort members alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis 
of the index case. Matching characteristics were study center (to account for centre-specific 
differences such as questionnaire design and blood collection procedures), sex, age, time of blood 
collection and fasting status at the time of blood collection (less than 3 hours, 3-6 hours, and more 
than 6 hours). Women were also matched on menopausal status (premenopausal, peri-menopausal, 
postmenopausal, or surgically menopausal). Premenopausal women were matched on phase of the 
menstrual cycle at blood collection, and postmenopausal women were matched on current use of 
hormone replacement therapy.  
Laboratory analyses  
Serum levels of glycer-AGEs were measured with a competitive enzyme-linked 
immunosorbent assay (ELISA) at Kanazawa Medical University, Japan by using immunopurified 
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glycer-AGEs antibody as described previously (15). Briefly, 96-well microtiter plates were coated with 
1 µg/mL glycer-AGEs to each well and incubated overnight in a cold room. Wells were washed three 
times with 0.3 mL of phosphate-buffered saline (PBS)-Tween-20 (PBS-Tween-20). Wells were then 
blocked by incubation for 1 hour with 0.2 mL of a solution of PBS containing 1% bovine serum 
albumin (BSA). After washing with PBS-Tween-20, test samples (50 µL) were added to each well as a 
competitor for 50 µL of glycer-AGEs antibody (1:1,000), followed by incubation for 2 hours at 30˚C 
with gentle shaking on a horizontal rotary shaker. Wells then were washed with PBS-Tween-20 and 
developed with an alkaline phosphatase-linked anti-rabbit IgG utilizing p-nitrophenyl phosphate as 
the colorimetric substrate. Results are expressed as glycer-AGEs units (U) per millilitre (mL) of serum, 
with 1 U corresponding to 1 µg of glycer-AGEs standard. Sensitivity and intra- and inter-assay 
coefficients of variation were 0.01 U/mL, 6.2 and 8.8%, respectively (31, 40). For all analyses, 
laboratory technicians were blinded to the case-control status of the samples and cases and matched 
controls were run on the same plate.  
Some existing biomarker measures on the same cases and matched controls were also 
utilized for this study. Measurements of glycated haemoglobin (HbA1c) were previously run on 
erythrocyte hemolysate using high performance liquid chromatography method (Bio-Rad Variant II 
instrument, Bio Lad Laboratories, Hercules, California) with intra-batch coefficient of variations of 2.5% 
(41). High-sensitivity C-reactive protein (hs-CRP) and high-density lipoprotein (HDL) cholesterol 
concentrations were measured using a high-sensitivity assay (Beckman-Coulter, Woerden, the 
Netherlands) and a colorimetric method, respectively, on a Synchron LX-20 Pro auto-analyzer 
(Beckman-Coulter). The inter-assay coefficients of variation were 6.0% - 6.5% and 3.4% - 4.1% at 
various concentrations of hs-CRP and HDL cholesterol, respectively (42). 
Statistical analysis 
The distributions of selected baseline demographic and dietary characteristics between colon 
and rectal cancer cases and the matched controls were described.  
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Conditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence 
intervals (CI) of CRC, and by anatomical sub-site of cancers of the colon and rectum in relation to 
levels of circulating glycer-AGEs. Glycer-AGEs levels were ranked into quartiles whose cut-points 
were determined based on the distribution among the controls with the lowest quartile as the 
reference category.    
Risk estimates were computed as both univariate analyses based on the matching factors, 
and multivariable analyses, with additional adjustments for potential confounders including smoking 
status (status/duration/intensity of smoking), body mass index (BMI, kg/m2), education level (as an 
indicator variable for socioeconomic status), total alcohol consumption (g/day), physical activity 
(combined recreational and household activity; expressed as sex-specific categories of metabolic 
equivalents), total energy intake (kcal/day), total daily intakes of fibre (g/day), fruits and vegetable 
(g/day), and red/processed meats (g/day) (43-48), and diabetes status (49, 50). Subjects were 
classified as diabetic if they had baseline HbA1c levels ≥6.5% and/or self-reported diabetes at 
recruitment (n = 174). For all models, collinearity was assessed and tests for linear trend were 
performed using a score variable with values from 1 to 4, consistent with the quartile grouping. 
Statistical tests for heterogeneity to test whether the associations differ by anatomical sub-sites of 
colon and rectal cancer were based on χ2 statistics. 
We also assessed effect modification by several factors; sex and tumour location were 
hypothesised as effect modifiers at the time of study design because of their modifying effect of 
some CRC risk factors in previous studies (4), while smoking, alcohol, and BMI were examined for 
hypothesis generation. The product term of glycer-AGEs (in quartiles) and each potential effect 
modifier was included in the model, and evaluated by a likelihood ratio test. In the sensitivity analysis, 
we repeated the main multivariable-adjusted models after excluding cases that occurred in the first 2 
years of the follow-up (n = 142 for colon and n = 82 for rectum) and their matched controls to avoid 
possible reverse causality, and subjects with diabetes and their matched cases and controls (n = 180 
for colon and n = 128  for rectum). Heterogeneity tests were based on χ2 statistics. 
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Logistic restricted cubic spline models were used to explore possible deviation from non-
linear relationships between glycer-AGEs and CRC, with 4 knots specific at the median of each 
quartile of glycer-AGEs levels.   
A two-tailed p-value < 0.05 was considered to be statistically significant. All statistical 
analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC) statistical software package. 
 
RESULTS 
Baseline characteristics of cases and controls 
Selected baseline characteristics of the colon and rectal cancer cases and their matched 
controls are compared in Table 1.  Colon and rectal cancer cases were on average 59 years and 58 
years old and had mean follow-up times of 3.7 and 3.9 years, respectively.  Colon cancer cases 
included a higher proportion of individuals who reported being physically inactive (15.8% vs. 11.5%), 
had higher average hs-CRP levels (3.1 vs. 2.2 mg/l), and consumed less fruits and vegetables (369 g/d 
vs. 418 g/d) than their matched controls. Both colon and rectal cancer cases were more likely to be 
diabetic (10.2% vs. 6.9% for colon and 11.7% vs. 8.0% for rectal cancer) than their counterparts. No 
significant case-control differences were observed in other baseline characteristics. 
Associations of glycer-AGEs with CRC  
Table 2 presents ORs and 95% CIs for the association between glycer-AGEs levels, in quartiles 
using the lowest category as a referent, and CRC. Overall, models with adjustments for matching 
factors showed very similar results with the multivariable models with adjustments for established 
confounding factors in addition to matching factors.  Elevated glycer-AGEs levels were not associated 
with CRC risk (multivariable adjusted OR = 1.10; 95% CI, 0.82-1.49, comparing highest vs. lowest 
quartiles; ptrend = 0.87). When analyses were run separately for CRC sub-sites, no association was 
observed between glycer-AGEs and risk of colon cancer (multivariable adjusted OR = 0.83; 95% CI, 
0.57-1.22; ptrend = 0.25), while a statistically significant positive association was observed with rectal 
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cancer (multivariable adjusted OR = 1.90; 95% CI, 1.14-3.19; ptrend = 0.04); although the test for 
heterogeneity was not statistically significant (Pheterogeneity=0.14).  
After testing potential effect modification by various factors relevant for CRC risk and glycer-
AGEs concentrations, alcohol consumption showed a statistically significantly modifying effect on the 
association between glycer-AGEs level and rectal cancer (pinteraction = 0.03). Further stratification by  
level of alcohol consumption (dichotomized based on the sex-specific median values of total alcohol 
consumption among controls; men, 18.1 g/d; women, 5.7 g/d) showed a significant, positive 
association for rectal cancer among high alcohol consumers (> median) group (multivariate adjusted 
OR = 2.70; 95% CI, 1.29-5.62; ptrend = 0.01) (Table 3). No significant effect modifications, including 
alcohol consumption, were observed for colon cancer. 
Sensitivity analysis 
After exclusion of cases which occurred during the first two years of follow-up and their 
matched controls, the overall findings did not change substantially for either of the CRC, colon or 
rectum anatomical sites. The associations between glycer-AGEs and CRC, colon, and rectal cancer 
risks were also similar after excluding subjects with diabetes. Spline models confirmed that 
associations between glycer-AGEs and risk of colon or rectal cancers were linear. 
 
DISCUSSION  
In this nested case-control study within the large prospective EPIC cohort, we did not 
observe any overall association between increasing circulating levels of glycer-AGEs and CRC. 
However, sub-group analyses by anatomical sub-site showed a statistically significant positive 
association with risk of rectal cancer, particularly among those with higher alcohol consumption. We 
found no association between glycer-AGEs and colon cancer risk.  
  A role for AGEs in CRC development has been hypothesized (37) but not yet fully explored. 
This may be due to the complexity of this family of compounds, whose heterogeneous structures are 
far from being fully understood (51). Of the handful of different AGEs species identified, N-
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(carboxymethyl)-lysine (CML) is probably among the most studied and is inferred as an indicator of 
overall AGEs exposure. The only evidence to date from prospective studies on blood CML measures 
shows no association with risk of CRC (36) or pancreatic cancer (52), results which are in line with our 
present findings for CRC, although we studied a different and possibly more toxic species of AGEs 
(14).  
 Our sub-group observations of a risk for rectal but not colon cancer are interesting. One 
explanation is chance, given the limited sample size of the rectal cancer sub-group and the non-
statistically significant test for heterogeneity of effect between the anatomical sub-sites. However, 
there are some possible biologic explanations for this observation: (a) Colon and rectal tissues may 
differ in expression level of the receptors that either bind AGEs (i.e. RAGE) and then elicit various 
pro-tumorigenic effects (53), or those that act as competitive inhibitors of RAGE-mediated signalling 
pathways, i.e. soluble form of RAGE (sRAGE) (54). Glycer-AGEs have been shown to have high binding 
affinity for RAGE (34), and decreased circulating sRAGE levels have been observed in CRC (36). If 
RAGE and sRAGE expression and activity levels differ between colon and rectal tissues, then a 
difference of effect associated with AGEs exposure may be plausible. In the current literature, there 
is some evidence indicating an increase in RAGE expression in human colon tissues in Crohn’s disease 
(55), and in the colon tissue of diabetic rats (56), but direct comparisons of human colon versus rectal 
normal and tumour tissues have not been reported and would warrant further study. (b) AGEs-
induced effects and AGEs accumulation may vary in tumors from different anatomical sites (24), 
resulting in tissue-specific effects of glycer-AGEs or AGEs in general. And (c) colon and rectal tumours 
differ by gene mutations (e.g. K-ras and APC gene) and biological behaviour (57-59), indicating that 
they may arise from different mechanisms of carcinogenesis and hence be differentially affected by 
various endogenous and exogenous factors, such as AGEs. Thus, although they are plausible, our 
findings of a differential association between the colon and rectal anatomical sub-sites require both 
replication and further study.  
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A related incidental observation in our sub-group analyses was a statistically significant effect 
modification of alcohol on the association between glycer-AGEs and rectal cancer risk. Although 
alcoholic beverages may be important exogenous sources of AGEs (60) and several studies, including 
our own (48), have observed a stronger association between higher alcohol consumption and 
development of rectal than colon cancer (61, 62), these observations do not explain the modifying 
effect of alcohol on the association of AGEs with rectal cancer that we observed. The reasons for this 
modification are therefore unclear and, if the modification were replicated, would warrant further 
study.   
The present study has several strengths. The foremost is the prospective design and the pre-
diagnostic collection of dietary/lifestyle information and blood samples from the cohort participants. 
Our study was also large and well powered to explore associations with CRC, but size was a limiting 
factor in our sub-group analyses. A key limitation of our study is that we only had a single measure of 
glycer-AGEs, taken at time of recruitment into the cohort (baseline). While there is no information as 
to what extent a single measure of AGEs reflects long term exposure, random errors in measuring 
long term exposure would be expected to reduce any observed disease risk associations towards the 
null. The finding of a significant association between glycer-AGEs and the risk of rectal cancer 
suggests that any measurement error was not sufficient to obscure the association, though the 
relative risks we observe may underestimate the strength of the true association.   
In summary, in this prospective study in European populations, circulating glycer-AGEs were 
not associated with overall risk of CRC. Further research is needed to investigate the role of glyer-
AGEs and AGEs in general in CRC development. 
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Table 1:  Description of cases and matched controls, by anatomical site 
Characteristics Colon Cancer Rectal Cancer
Cases Matched Controls Cases Matched Controls
Men, n  
Women, n  
Total 
297
362 
659 
297
362 
659 
213
183 
396 
213
183 
396 
Age, years, mean (SD) 
     At recruitment 
     At blood collection 
58.8 (7.2) 
59.0 (7.2) 
58.8 (7.2) 
58.9 (7.2) 
58.1 (6.8) 
58.1 (6.8) 
57.7 (6.6) 
57.8 (6.5) 
Body mass index, kg/m2, mean (SD) 26.8 (4.5) 26.3 (3.9) 26.6 (4.0) 26.4 (3.8)
Waist circumference, cm, mean (SD) 90.4 (13.3) 88.0 (12.1) 90.4 (12.9) 89.8 (12.9)
Smoking status/duration/intensity, n (%)
     Never-smokers 
     Ex-smokers, duration of smoking <10 years 
     Ex-smokers, duration of smoking >10 years 
     Ex-smokers, missing duration of smoking 
     Smokers, <15 cigarettes a day 
     Smokers, >15 to <25 cigarettes a day 
     Smokers, >25 cigarettes a day 
     Missing smoking status 
276 (41.9) 
40 (6.1) 
160 (24.3) 
15 (2.3) 
110 (16.7) 
41 (6.2) 
9 (1.4) 
8 (1.2) 
291 (44.2) 
43 (6.5) 
165 (25.0) 
12 (1.8) 
96 (14.6) 
39 (5.9) 
6 (0.9) 
7 (1.1) 
155 (39.1) 
21 (5.3) 
103 (26.0) 
4 (1.0) 
79 (19.9) 
24 (6.1) 
7 (1.8) 
3 (0.8) 
156 (39.4) 
29 (7.3) 
93 (23.5) 
8 (2.0) 
65 (16.4) 
34 (8.6) 
5 (1.3) 
6 (1.5) 
Physical activity, n (%) 
     Inactive 
     Moderately inactive 
     Moderately active 
     Active 
     Missing/unspecified 
Education level, n (%) 
     None/primary 
     Technical/professional 
     Secondary 
     University or higher 
     Missing/unspecified 
104 (15.8) 
201 (30.5) 
288 (43.7) 
62 (9.4) 
4 (0.6) 
 
256 (38.8) 
151 (22.9) 
113 (17.1) 
117 (17.7) 
22 (3.3) 
76 (11.5) 
206 (31.3) 
293 (44.5) 
78 (11.8) 
6 (0.9) 
 
288 (43.7) 
161 (24.4) 
83 (12.6) 
109 (16.5) 
18 (2.7) 
57 (14.4) 
115 (29.0) 
176 (44.4) 
48 (12.1) 
0 
 
147 (37.1) 
108 (27.3) 
54 (13.6) 
75 (18.9) 
12 (3.0) 
58 (14.6) 
99 (25.0) 
169 (42.7) 
61 (15.4) 
9 (2.3) 
 
163 (41.2) 
110 (27.8) 
41 (10.3) 
75 (18.9) 
7 (1.8) 
Diabetes status, % 
     Self-reported diabetes at recruitment, n (%) 
     Subjects HbA1c > 6.5%, n (%) 
29 (5.3) 
54 (10.0) 
29 (5.3) 
25 (6.1) 
24 (6.9) 
36 (11.1) 
16 (4.6) 
22 (8.6) 
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     Self-reported diabetes or HbA1c > 6.5%, n (%)
Dietary variables (g/day, median (IQR)) 
     Total energy, kcal/day 
     Total fat intake, 
     Fibre intake 
     Fruit and vegetable intake 
     Red meat intake 
     Processed meat intake 
     Alcohol intake 
Hs-CRP, mg/l, median (IQR) 
Cholesterol, mmol/L, median (IQR) 
HDL, mmol/L, median (IQR) 
LDL, mmol/L, median (IQR) 
Glycer-AGEs, U/mL, median (IQR) 
65 (10.2)
 
2070 (1690-2490) 
77 (60-96) 
22 (17-27) 
369 (246-524) 
48 (25-77) 
25 (13-41) 
9 (1-23) 
3.1 (1.3-5.7) 
6.3 (5.5-7.1) 
1.4 (1.1-1.7) 
4.2 (3.5-4.8) 
6.8 (5.3-8.3) 
42 (6.9)
 
2060 (1730-2450) 
77 (61-96) 
23 (18-27) 
418 (263-566) 
48 (26-76) 
23 (12-42) 
8 (1-21) 
2.2 (1.1-4.7) 
6.4 (5.6-7.2) 
1.4 (1.2-1.8) 
4.2 (3.5-4.9) 
7.0 (5.5-8.7) 
45 (11.7)
 
2150 (1730-2560) 
79 (60-104) 
22 (18-28) 
356 (244-504) 
56 (34-84) 
27 (14-47) 
12 (2-31) 
2.3 (1.0-4.4) 
6.4 (5.6-7.1) 
1.4 (1.2-1.7) 
4.2 (3.4-4.8) 
7.2 (5.8-9.1) 
30 (8.0)
 
2110 (1720-2560) 
80 (63-103) 
23 (18-28) 
364 (250-524) 
54 (31-82) 
26 (13-47) 
11 (2-25) 
2.3 (1.0-4.2) 
6.5 (5.8-7.3) 
1.4 (1.2-1.7) 
4.3 (3.6-5.0) 
7.1 (5.4-8.6) 
NOTE:  Cases and controls were matched on age (within 2.5 years), gender, administrative centre, hormone therapy and menopausal status (among women), 
fasting status, and date of blood collection (within 45 days)   
Abbreviation:  SD = standard deviation; IQR = inter-quartile range; hs-CRP = high-sensitivity C-reactive protein; HDL = high-density lipoprotein; LDL = low-density 
lipoprotein; Glycer-AGEs = glyceraldehyde-derived advanced glycation end-products 
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Table 2:  Circulating glycer-AGEs concentration and the risk of cancers of the colorectum, colon, and rectum 
Type of Cancer 
Glycer-AGEs
ptrend Q1 (reference)
OR  
Q2
OR (95% CI) 
Q3 
OR (95% CI) 
Q4
OR (95% CI) 
Colorectum                       
Cut-point [U/mL]a 
Mean (SD), median [U/mL] 
<5.42
4.3 (0.9), 4.4 
>5.42 and <7.03
6.3 (0.5), 6.3 
>7.03 and <8.65
7.8 (0.4), 7.7 
>8.65
10.5 (1.7), 10.0 
Number of cases/controls 
Matching factorsb 
Multivariate adjustedc 
249/264
1.00 
1.00 
301/264
1.19 (0.94-1.50) 
1.18 (0.92-1.51) 
237/263
0.95 (0.74-1.23) 
0.94 (0.72-1.24) 
266/263
1.07 (0.81-1.42) 
1.10 (0.82-1.49) 
0.95 
0.87 
Colon 
Cut-point [U/mL]a 
Mean (SD), median [U/mL] 
Number of cases/controls 
Matching factorsb 
Multivariate adjustedc 
<5.48
4.3 (0.9), 4.5 
174/166 
1.00 
1.00 
>5.48 and <6.99  
6.3 (0.5), 6.2 
184/165 
1.03 (0.77-1.37) 
1.04 (0.76-1.42) 
>6.99 and <8.68
7.7 (0.5), 7.7 
157/164 
0.88 (0.64-1.20) 
0.86 (0.61-1.22) 
>8.68
10.5 (1.7), 10.0 
144/164 
0.78 (0.55-1.11) 
0.83 (0.57-1.22) 
 
 
0.12 
0.25 
Rectum 
Cut-point [U/mL]a 
Mean (SD), median [U/mL] 
Number of cases/controls 
Matching factorsb 
Multivariate adjustedc 
<5.36
4.2 (1.0), 4.4 
77/99 
1.00 
1.00 
>5.36 and <7.12  
6.3 (0.5), 6.4 
115/100 
1.49 (0.99-2.23) 
1.47 (0.96-2.27) 
>7.12 and <8.61  
7.8 (0.4), 7.7 
79/98 
1.14 (0.73-1.80) 
1.11 (0.68-1.80) 
>8.61
10.3 (1.7), 9.5 
125/99 
1.90 (1.17-3.10) 
1.90 (1.14-3.19) 
 
 
0.03 
0.04 
   a Based on control participants only 
   b Model based on matching factors (age, gender, administrative centre, time of the day at blood collection, fasting status, and menopausal status among   
   women) only 
   c Model based on matching factors plus adjustments for smoking status/duration/intensity, body mass index, total physical activity, education level,     
   diabetes status, total dietary energy consumption, and intakes of alcohol, red and processed meat, fibre, and fruits and vegetable 
   Abbreviation: Glycer-AGEs = glyceraldehyde-derived advanced glycation end-products; Q = quartile; OR = odds ratio; CI = confidence interval 
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Table 3:  Odds ratios (95% CI) for colon and rectal cancer according to quartiles of circulating glycer-AGEs by alcohol intake status 
Sex specific categories of  
dietary alcohol intake level (g/day) 
Glycer-AGEsa
ptrend Q1
OR 
Q2
OR (95% CI) 
Q3
OR (95% CI) 
Q4
OR (95% CI) 
Colon 
Low alcohol status (< median)b  
     Number of cases/controls  
     Matching factorsc 
     Multivariate adjustedd 
High alcohol status (> median)b 
     Number of cases/controls 
     Matching factorsc 
     Multivariate adjustedd 
 
135/130 
1.00 
1.00 
 
39/36 
1.00 
1.00 
 
145/137 
0.97 (0.69-1.37) 
1.01 (0.69-1.47) 
 
39/28 
1.48 (0.68-3.20) 
1.10 (0.46-2.61) 
 
 
119/119 
0.79 (0.54-1.15) 
0.79 (0.52-1.20) 
 
38/45 
0.92 (0.40-2.07) 
0.78 (0.31-1.95) 
 
104/124 
0.71 (0.46-1.10) 
0.82 (0.51-1.33) 
 
40/40 
1.11 (0.47-2.58) 
1.17 (0.46-3.03) 
 
 
0.08 
0.29 
  
 
0.95 
0.95  
Rectum 
Low alcohol status (< median)b 
     Number of cases/controls 
     Matching factorsc 
     Multivariate adjustedd 
High alcohol status (> median)b 
     Number of cases/controls 
     Matching factorsc  
     Multivariate adjustedd 
51/64 
1.00 
1.00 
 
26/35 
1.00 
1.00 
70/57 
1.56 (0.92-2.65) 
1.48 (0.85-2.58) 
 
45/43 
1.39 (0.69-2.77) 
1.41 (0.69-2.88) 
38/46 
0.95 (0.52-1.73) 
0.95 (0.51-1.78) 
 
40/52 
1.14 (0.57-2.29) 
1.07 (0.52-2.19) 
57/63 
1.14 (0.66-1.97) 
1.14 (0.64-2.03) 
 
68/36 
2.85 (1.41-5.79) 
2.70 (1.29-5.62) 
 
0.95 
0.99 
 
 
< 0.01 
0.01 
   a Quartile cut-offs are same as in Table 2 
   b Alcohol consumption level was dichotomized based on the sex-specific median values of lifetime alcohol consumption among controls 
                   c Model adjusted for matching factors (age, gender, administrative centre, time of the day at blood collection, fasting status, and menopausal status among   
                    women) only 
                   d Model adjusted for matching factors plus smoking status/duration/intensity, body mass index, total physical activity, education level, diabetes status,            
                   total dietary energy consumption, red and processed meat, fibre, and fruits and vegetable 
                   Abbreviation: Glycer-AGEs = glyceraldehyde-derived advanced glycation end-products; Q = quartile; OR = odds ratio; CI = confidence interval 
 
 
 
o
n
 N
ovem
ber 2, 2016. © 2015 Am
erican Association for Cancer Research. 
cebp.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on Septem
ber 24, 2015; DO
I: 10.1158/1055-9965.EPI-15-0422 
 Published OnlineFirst September 24, 2015.Cancer Epidemiol Biomarkers Prev 
  
So Yeon Kong, Masayoshi Takeuchi, Hideyuki Hyogo, et al. 
  
Glycation End-Products and Colorectal Cancer Risk
The Association between Glyceraldehyde-derived Advanced
  
Updated version
  
 10.1158/1055-9965.EPI-15-0422doi:
Access the most recent version of this article at:
  
Manuscript
Author
edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
on November 2, 2016. © 2015 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 24, 2015; DOI: 10.1158/1055-9965.EPI-15-0422 
